FDA approves Breo Ellipta, a new once-daily COPD inhaler treatment
www.pulmccm.org
FDA Approves Breo Ellipta, Once-Daily LABA/ICS for COPD The FDA approved the new drug Breo Ellipta as a once-daily inhaled therapy for chronic obstructive pulmonary disease (COPD). Breo Ellipta includes the corticosteroid fluticasone, and vilanterol -- a once-daily long acting beta agonist -- in a combination dry powder inhaler. This was the FDA's first approval of the LABA vilanterol.
FDA approves Breo Ellipta, a new once-daily COPD inhaler treatment
FDA approves Breo Ellipta, a new once-daily…
FDA approves Breo Ellipta, a new once-daily COPD inhaler treatment
FDA Approves Breo Ellipta, Once-Daily LABA/ICS for COPD The FDA approved the new drug Breo Ellipta as a once-daily inhaled therapy for chronic obstructive pulmonary disease (COPD). Breo Ellipta includes the corticosteroid fluticasone, and vilanterol -- a once-daily long acting beta agonist -- in a combination dry powder inhaler. This was the FDA's first approval of the LABA vilanterol.